192
Views
13
CrossRef citations to date
0
Altmetric
Original Article

The combined use of three widely available biochemical markers as predictor of organ failure in critically ill patients

ORCID Icon, ORCID Icon, ORCID Icon, & ORCID Icon
Pages 479-485 | Received 28 Dec 2015, Accepted 12 Jun 2016, Published online: 30 Jun 2016
 

Abstract

Background: We hypothesized that lactate dehydrogenase, LDH/albumin ratio in combination with or without magnesium (Mg2+) could predict organ failure in critically ill adult patients. The aim of this study was to describe a new risk index for organ failure or mortality in critically ill patients based on a combination of these routinely available biochemical plasma biomarkers.

Methods: Patients≥ 18 years admitted to the intensive care unit (ICU) were screened. Albumin and LDH were analyzed at the time of admission to ICU (n = 347). Organ failure assessed with ‘Sequential Organ Failure Assessment’ (SOFA) score was used, and 30-day mortality was recorded. The predictive value of the test was calculated using the areas under the receiving operating characteristic (ROC) curve.

Results: The LDH/albumin ratio was higher in patients who developed organ failure as compared to those who did not (p < 0.001). The areas under the ROC curve were 0.77 both for prediction of multiple organ failure and for 30-day mortality. In a subgroup of patients (n= 183) admitted to ICU from the emergency department, the predictive values were 0.86 and 0.80, respectively.

Conclusion: The LDH/albumin ratio at ICU admission was associated with the development of multiple organ failure and 30-day mortality in this prospective study. The clinical value of this biomarker as a predictor of organ failure in critically ill patients is yet to be defined.

Acknowledgements

The Center for Clinical Research at the County Council of Värmland, Sweden, supported this work. Thanks to Tara Zaferanlou for language editing. Many thanks to the staff in our ICU.

Disclosure statement

The authors F.H., J.W., L.W. or J.R. report no conflicts of interest. MK is the founder and co-owner of a medical-technology start-up company (http://www.calmark.se) that develops diagnostic devices for point-of-care analysis of LDH and may therefore gain future benefits from the results of the present trial. The authors alone are responsible for the content and writing of the paper.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 200.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.